Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 24 June 2014 | By Alexander Gaffney, RAC,
A Canadian subsidiary of pharmaceutical company GlaxoSmithKline (GSK) has been accused by the US Food and Drug Administration (FDA) of deviating from good manufacturing practice (GMP) regulations while manufacturing the flu vaccine FluLaval.
The allegations, contained in a Warning Letter released by FDA on 24 June 2014, stem from a 31 March-9 April 2014 inspection of ID Biomedical Corporation's—a GSK subsidiary since 2005—Quebec facility.
The bulk of the allegations contained within FDA's Warning Letter focus on a general failure to maintain microbiological controls at or above federal standards.
For example, FDA claimed that the purified water used in the manufacture of FluLaval was "inadequate to prevent bioburden and endotoxin excursions," or in plain terms, that the water wasn't free of microorganisms. FDA said records examined by its inspectors indicated several instances over the last two years when ID Biomedical employees had discovered bacteria and other organisms in the water, and commented that the company lacked a "set schedule" for disinfecting the water system at regular intervals.
FDA inspectors also expressed concern about the company's manufacturing controls, which it claimed had been insufficient to control contamination and/or endotoxins. Those problems had existed for years despite attempts to correct them, FDA observed.
In another case, FDA said it had observed documents indicating that the company had been unable to determine if lots of its vaccine— an inactivated virus incapable of causing the flu—had in fact been inactivated, potentially leaving patients at risk.
FDA said the totality of the deficiencies noted in the Warning Letter—a type of letter threatening future enforcement action unless actions are taken to address the agency's concerns—were "an indication of your quality control unit not fulfilling its responsibility to assure the identity, strength, quality, and purity of your licensed biological drug product and intermediates."
"FDA expects ID Biomedical and GSK to undertake a comprehensive and global assessment of all of its manufacturing operations to ensure that all products conform to FDA requirements," FDA wrote. "Given the potential contributions of Flulaval to the public health, we encourage frequent interaction between your management and technical staff with FDA to help ID Biomedical and GSK move forward with corrective actions as rapidly as possible."
FDA said GSK had already been in contact with the agency three times, and that regulators had requested a meeting with the company's senior management to "discuss the issues cited in this letter"—a highly unusual measure rarely mentioned in FDA Warning Letters.
Tags: Warning Letter, Inspection, Vaccine, Flu Vaccine, Influenza Vaccine, FluLaval
Regulatory Focus newsletters
All the biggest regulatory news and happenings.